Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 28 versus MIBELAS 24 FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 28 versus MIBELAS 24 FE.
BALZIVA-28 vs MIBELAS 24 FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-28 is a combination estrogen-progestin oral contraceptive. Ethinyl estradiol provides estrogenic activity, while levonorgestrel acts as a progestin, primarily suppressing gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, and causing changes in cervical mucus and endometrium to reduce sperm penetration and implantation.
Combination hormonal contraceptive: ethinyl estradiol suppresses LH and FSH, primarily inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity, increasing cervical mucus viscosity and altering endometrial morphology.
One tablet (0.5 mg levonorgestrel and 0.1 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
One tablet orally once daily for 24 days followed by 4 placebo tablets. Each tablet contains 75 mcg desogestrel and 0.02 mg ethinyl estradiol.
None Documented
None Documented
2.5 hours; clinically relevant for dosing interval in renal impairment
Drospirenone: ~30 hours; Ethinyl estradiol: ~17 hours. Steady-state reached after ~10 days for drospirenone.
Renal: 50-60% as unchanged drug; fecal: 30-40% as metabolites; biliary: <5%
Drospirenone: 40-50% renal as metabolites, <10% unchanged; ~50% fecal. Ethinyl estradiol: ~40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive